Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
140 participants
INTERVENTIONAL
2010-06-30
2011-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
placebo
Dose treatment group, 10%
placebo
Therapeutic dose of 10%
Xinju Xiaogao Prescription
treatment group
Xinju Xiaogao Prescription
treatment group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Xinju Xiaogao Prescription
treatment group
placebo
Therapeutic dose of 10%
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI≥28kg/m2，but\<40kg/m2
* Waistline≥85cm（male）,≥80cm（female）
* Pathoglycemia must fulfill one of those four condition:
* IGT,7.8≤2hPG≤11.0mmol/,
* diabetics take medicine used to treat type 2 diabetes more than 3 month,and 5.6≤FBG≤12.2,and weight change under 4kg.
* stagnation of QI causing phlegm retention
* To sign informed consent.
Exclusion Criteria
* TG\>4.5mmol/L.
* Suffering from congenital heart disease, rheumatic heart disease, kidney disease, serious active liver disease, peptic ulcer disease or malabsorption syndrome.
* There is a history of pancreatitis or endocrine diseases other than diabetes, diabetes treated with insulin.
* Not suffered myocardial infarction in Past 3 months or unstable angina were confirmed.
* Had been diagnosed as "post-surgical adhesions" .
* There is a history of appetite or abuse of laxatives
* Diastolic blood pressure,uncontrolled or controlled, three times greater than 105mmHg .
* Pregnancy, prepare to pregnant or lactating women prepare.
* Allergies to Chinese medicine , allergic.
* Recurrent gallstone or a history of kidney stones.
* Mentally ill.
* Cancer patients.
* A history of gastrointestinal surgery to lose weight.
* Receiving other clinical studies nearly 3 months.
* Alcohol and / or psychoactive substances, drug abusers and addicts.
* Taking other weight-reducing aid Close within one month
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
China-Japan Friendship Hospital
OTHER
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
OTHER
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fengmei Lian
chief
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fenglian Li, PHD
Role: STUDY_DIRECTOR
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
19850701
Identifier Type: -
Identifier Source: org_study_id